Vaxxinit - Model UB-312 - Neurodegeneration

Targets toxic forms of aggregated α-synuclein in the brain to fight Parkinson’s and other synucleinopathies, such as dementia with Lewy Body (“DLB”) and multiple system atrophy (“MSA”). The first part of a Phase 1 trial in healthy volunteers has shown UB-312 to be well tolerated, with no significant safety findings, and immunogenic, with a high responder rate and antibodies that cross the blood-brain barrier (“BBB”).